Workflow
EDAN(300206)
icon
Search documents
理邦仪器(300206) - 2024年度监事会工作报告
2025-04-23 12:01
2024 年度监事会工作报告 (四)第五届监事会 2024 年第四次会议于 2024 年 10 月 24 日在公司以现场 会议方式召开,会议审议通过《2024 年第三季度报告》的议案。 (五)第五届监事会 2024 年第五次会议于 2024 年 11 月 20 日在公司以现场 会议方式召开,会议审议通过《关于注销回购专用证券账户股份》、《关于变更公 深圳市理邦精密仪器股份有限公司 2024 年度监事会工作报告 2024 年度,深圳市理邦精密仪器股份有限公司(以下简称"公司")监事会 严格遵守《公司法》、《公司章程》等有关规定,以维护公司利益和股东权益为原 则勤勉尽责,参加了历次股东大会,列席董事会会议,对公司经营活动、财务状 况、重大决策、股东大会召开程序以及董事、高级管理人员履行职责情况等方面 实施了有效监督,较好地保障了公司股东权益、公司利益和员工的合法权益,促 进了公司的规范化运作。现将 2024 年公司监事会主要工作情况汇报如下: 一、报告期内监事会会议情况 报告期内,公司共召开 5 次监事会会议,会议情况如下: (一)第五届监事会 2024 年第一次会议于 2024 年 3 月 28 日在公司以现场 ...
理邦仪器(300206) - 关于公司会计政策变更的公告
2025-04-23 12:01
深圳市理邦精密仪器股份有限公司 证券代码:300206 证券简称:理邦仪器 公告编号:2025-016 深圳市理邦精密仪器股份有限公司 关于公司会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司(以下简称"公司")根据中华人民共和 国财政部(以下简称"财政部")发布的《企业会计准则解释第 17 号》及《企 业会计准则解释第 18 号》(以下简称"准则解释第 17 号""准则解释第 18 号")的相关规定,对公司相关会计政策进行变更,本次变更不会对公司财务状 况、经营成果和现金流量产生重大影响。具体情况公告如下: 一、会计政策变更概述 1、变更的性质 根据法律、行政法规或者国家统一的会计制度的要求变更会计政策。 2、变更的原因 2023 年 10 月 25 日,财政部发布了《关于印发〈企业会计准则解释第 17 号〉 的通知》(财会〔2023〕21 号),对"关于流动负债与非流动负债的划分"、"关于 供应商融资安排的披露"以及"关于售后租回交易的会计处理"的内容进行进一 步规范及明确。该解释自 2024 年 1 月 ...
理邦仪器(300206) - 独立董事提名人声明与承诺(郑全录)
2025-04-23 12:01
深圳市理邦精密仪器股份有限公司 证券代码:300206 证券简称:理邦仪器 公告编号:2025-019 如否,请详细说明:______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不 得担任公司董事的情形。 √ 是 □ 否 如否,请详细说明:______________________________ 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券 交易所业务规则规定的独立董事任职资格和条件。 深圳市理邦精密仪器股份有限公司 独立董事提名人声明与承诺 提名人深圳市理邦精密仪器股份有限公司第五届董事会现就提名郑全录为 深圳市理邦精密仪器股份有限公司第六届董事会独立董事候选人发表公开声明。 被提名人已书面同意作为深圳市理邦精密仪器股份有限公司第六届董事会独立 董事候选人(参见该独立董事候选人声明)。本次提名是在充分了解被提名人职 业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况 后作出的,本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性 文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性 ...
理邦仪器(300206) - 董事会审计委员会关于对会计师事务所2024年度履职情况评估及履行监督职责情况的报告
2025-04-23 12:01
深圳市理邦精密仪器股份有限公司 深圳市理邦精密仪器股份有限公司 1 董事会审计委员会关于对会计师事务所2024年度履职情况 评估及履行监督责任情况的报告 深圳市理邦精密仪器股份有限公司(以下简称"公司")董事会审计委员会 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公司 自律监管指引第2号——创业板上市公司规范运作》等法律法规、规范性文件以 及《公司章程》《董事会审计委员会工作细则》等规定和要求,本着勤勉尽责的 原则,恪尽职守,认真履职。现将董事会审计委员会对会计师事务所2024年度履 职评估及履行监督职责的情况汇报如下: 一、2024年年审会计师事务所基本情况 (一) 会计师事务所基本情况 名称:信永中和会计师事务所(特殊普通合伙)(以下简称"信永中和") 成立日期:2012年3月2日 组织形式:特殊普通合伙企业注册地址:北京市东城区朝阳门北大街8号富 华大厦A座8层 首席合伙人:谭小青先生 截至2024年12月31日,信永中和合伙人259人,注册会计师1780人。签署过 证券服务业务审计报告的注册会计师人数超过 ...
理邦仪器(300206) - 独立董事提名人声明与承诺(吴瑛)
2025-04-23 12:01
深圳市理邦精密仪器股份有限公司 证券代码:300206 证券简称:理邦仪器 公告编号:2025-020 深圳市理邦精密仪器股份有限公司 独立董事提名人声明与承诺 提名人深圳市理邦精密仪器股份有限公司第五届董事会现就提名吴瑛为深 圳市理邦精密仪器股份有限公司第六届董事会独立董事候选人发表公开声明。被 提名人已书面同意作为深圳市理邦精密仪器股份有限公司第六届董事会独立董 事候选人(参见该独立董事候选人声明)。本次提名是在充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况后作 出的,本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性文件 和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求,具体声 明并承诺如下事项: 一、被提名人已经通过深圳市理邦精密仪器股份有限公司第五届董事会提 名委员会或者独立董事专门会议资格审查,提名人与被提名人不存在利害关系 或者其他可能影响独立履职情形的密切关系。 √ 是 □ 否 如否,请详细说明:______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不 得担 ...
理邦仪器(300206) - 关于使用闲置自有资金购买短期保本理财产品的公告
2025-04-23 12:01
证券代码:300206 证券简称:理邦仪器 公告编号:2025-009 深圳市理邦精密仪器股份有限公司 关于使用闲置自有资金购买短期保本理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司 为提高资金使用效率,合理利用闲置资金,增加公司收益,2025 年 4 月 23 日,深圳市理邦精密仪器股份有限公司(以下简称"公司")第五届董事会 2025 年第一次会议审议通过了《关于使用闲置自有资金购买短期保本理财产品》的议 案。在保证正常生产经营不受影响和风险可控的前提下,公司董事会同意使用不 超过人民币 6 亿元的闲置自有资金购买短期保本理财产品,现将有关事项公告如 下: 一、投资概况 1、投资目的 为提高公司资金使用效率,合理利用闲置资金,在不影响公司正常经营的情 况下,利用闲置自有资金购买保本型理财产品,增加公司收益,为公司及股东谋 取较好的投资回报。 2、投资额度 公司使用额度不超过人民币 6 亿元的闲置自有资金购买保本型理财产品。在 上述额度内,资金可以滚动使用。 3、投资品种 此次投资品种为一年以内的保本理财产品, ...
理邦仪器(300206) - 2024 Q4 - 年度财报
2025-04-23 12:00
Product Innovation and Development - In 2024, the company launched the i500 wet blood gas analyzer, significantly reducing testing time and optimizing sample processing, enhancing medical efficiency and patient experience [6]. - The company has launched several strategic new products, including the i500 fully automatic blood gas electrolyte analyzer and the Nano series handheld digital ultrasound diagnostic device, enhancing its product competitiveness [112]. - The company has developed the industry-first CNBP continuous non-invasive blood pressure measurement technology, widely accepted by top-tier hospitals [60]. - The company launched a comprehensive blood gas solution that includes a full range of products and a smart POCT software management platform, addressing pain points in traditional blood gas testing [85]. - The company aims to enhance brand influence and channel coverage while expanding ECG network coverage and promoting international localization [66]. - The company is developing a new product, the Six-Minute Walk Test System, aimed at expanding its ECG product line [162]. - The company is focusing on technological advancements, as evidenced by the registration of a new ECG system (Class IIa) designed for both adult and pediatric patients, effective from December 25, 2024 [180]. - The company is actively pursuing regulatory approvals for new products, with several devices set to expire between 2025 and 2029, ensuring a pipeline of future offerings [171]. Financial Performance - The company's operating revenue for 2024 was ¥1,834,376,591.62, a decrease of 5.35% compared to ¥1,937,988,917.83 in 2023 [32]. - Net profit attributable to shareholders for 2024 was ¥162,109,421.89, down 26.75% from ¥221,301,109.00 in 2023 [32]. - Basic earnings per share for 2024 were ¥0.2797, reflecting a decline of 26.74% from ¥0.3818 in 2023 [32]. - The company achieved operating revenue of 1,834.38 million yuan, a year-on-year decrease of 5.35%, with net profit attributable to shareholders of 162.11 million yuan, down 26.75% [120]. - Domestic market revenue was 736.22 million yuan, down 24.82%, while international market revenue reached 1,098.16 million yuan, an increase of 14.54% [121]. - The total non-recurring gains and losses amounted to CNY 18,455,169.03, a decrease from CNY 26,828,387.65 in the previous year, showing a reduction in non-recurring income [38]. - The company reported a net loss from investment activities of CNY 73,692,586.61, a 53.43% increase in losses compared to the previous year [192]. Market Expansion and Localization - The company achieved a nearly 90% localization rate for overseas employees, demonstrating commitment to local talent and international market penetration [8]. - The company established subsidiaries in Indonesia and France in 2024, improving overseas operations and market responsiveness [8]. - The company will continue to deepen localization efforts in key overseas markets, enhancing market penetration and resource integration [13]. - The company has established a global marketing network covering 34 domestic provinces and over 170 countries, continuously optimizing its marketing layout [115]. - The company has launched the Acclarix Nano series handheld ultrasound solution, focusing on maternal and fetal health in low to middle-income countries [163]. Research and Development - The company has invested over 2.71 billion yuan in R&D since its listing, with R&D expenditure for the reporting period amounting to 340.24 million yuan, accounting for 18.55% of the current operating income [112]. - The company holds a total of 1,243 valid patents, including 523 invention patents, 469 utility model patents, and 251 design patents, with 165 new patents granted during the reporting period [112]. - The company is committed to continuous investment in the IVD field, enhancing product performance and expanding product categories to strengthen its competitive advantage [89]. - The company has established four major R&D centers and 22 subsidiaries globally, focusing on continuous innovation and advanced technology development [57]. - The company is enhancing its research and development efforts, focusing on innovative medical devices such as a remote monitoring system (Class III) for real-time physiological data transmission, registered on September 23, 2024 [178]. Social Responsibility and Compliance - The company is committed to fulfilling social responsibilities while providing high-quality medical products and services [11]. - The company has established a compliance department in August 2024 to ensure adherence to international trade regulations and enhance risk management across key business areas [131]. - The company has received NMPA and EU MDR CE certifications for its blood gas analyzers, enhancing its competitive strength in the blood gas analysis field [84]. - The company has received regulatory approval for multiple diagnostic kits, including the ultra-sensitive C-reactive protein assay kit and D-dimer assay kit, with approval numbers 20222400538 and 20172401776 respectively [175]. Operational Efficiency - The company aims to improve operational efficiency by optimizing resource allocation and shortening product development cycles in 2025 [12]. - The cash flow from operating activities increased significantly by 145.99% to ¥371,360,642.18 in 2024, compared to ¥150,964,260.88 in 2023 [32]. - The company reported a significant increase in cash flow, indicating improved operational efficiency and potential for future investments [32]. - The company has optimized its organizational structure and established new subsidiaries in Indonesia to strengthen its global business layout [130]. Industry Trends and Market Outlook - The global medical device market is projected to reach USD 629.2 billion in 2024, with a compound annual growth rate (CAGR) of 5.71% until 2027 [42]. - China's medical device market is expected to reach CNY 1.15 trillion in 2024, with a CAGR of 10.2% from 2021 to 2025, indicating robust growth potential [47]. - The aging population in China is projected to reach 22% of the total population by 2040, driving increased demand for medical devices related to chronic disease management [49]. - The medical device industry is experiencing rapid growth, driven by increasing health demands, aging populations, and government policies favoring innovation and accelerated approvals [108].
理邦仪器(300206) - 2025 Q1 - 季度财报
2025-04-23 12:00
Revenue and Profit - Revenue for Q1 2025 was CNY 420,355,229.15, a decrease of 5.25% compared to CNY 443,644,512.37 in the same period last year[4] - Net profit attributable to shareholders increased by 68.98% to CNY 65,088,179.59 from CNY 38,517,609.83 year-on-year[4] - Basic and diluted earnings per share rose by 69.13% to CNY 0.1123 from CNY 0.0664 in the same period last year[4] - Net profit for the current period is ¥65,179,960.42, an increase of 67.5% compared to ¥38,866,635.68 in the previous period[32] - The company reported a total profit of ¥65,075,313.25, which is an increase of 64.5% from ¥39,580,516.66 in the previous period[32] - The company’s total comprehensive income for the current period is ¥64,996,759.94, up from ¥38,892,554.21 in the previous period, marking a growth of 67.2%[32] Cash Flow and Operating Activities - The net cash flow from operating activities decreased significantly by 86.46% to CNY 10,519,560.71 from CNY 77,719,605.62 in the previous year[21] - Cash flow from operating activities generated a net amount of ¥10,519,560.71, a significant decrease of 86.5% from ¥77,719,605.62 in the previous period[34] - The company’s investment activities resulted in a net cash outflow of ¥321,761,437.53, compared to a net outflow of ¥209,433,647.81 in the previous period[36] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,378,193,094.84, a decrease of 0.79% from CNY 2,397,044,407.74 at the end of the previous year[4] - The company's total liabilities decreased to CNY 305,437,345.35 from CNY 389,285,418.19, indicating a reduction of approximately 21.5%[29] - Cash and cash equivalents decreased to CNY 815,521,494.80 from CNY 1,123,799,045.12, representing a decline of approximately 27.4%[28] - The total non-current assets slightly decreased to CNY 711,307,853.62 from CNY 712,738,237.21, indicating a marginal decline[29] - The company reported a total of 1,666,885,241.22 in current assets, down from 1,684,306,170.53, a decrease of approximately 1.4%[28] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,431[24] - The total equity attributable to the parent company increased to CNY 2,073,332,816.64 from CNY 2,008,426,242.90, reflecting a growth of about 3.2%[30] - The company's retained earnings increased to CNY 954,139,879.05 from CNY 896,340,313.10, reflecting an increase of about 6.5%[29] Inventory and Receivables - Accounts receivable increased slightly to CNY 147,828,046.36 from CNY 145,953,596.03, showing a growth of about 1.3%[28] - Inventory decreased to CNY 337,643,309.64 from CNY 351,912,330.97, indicating a reduction of approximately 4.0%[28] Investment Income and Impairment Losses - Investment income surged by 569.03% to CNY 998,408.81 compared to a loss of CNY 212,867.73 in the same period last year[15] - The company experienced a 812.84% increase in credit impairment losses, amounting to CNY -850,359.19, due to increased provisions for accounts receivable[17] - The company incurred a credit impairment loss of ¥850,359.19, compared to a loss of ¥93,155.29 in the previous period[31]
理邦仪器:2024年净利润1.62亿元,同比下降26.75%
news flash· 2025-04-23 11:59
理邦仪器(300206)公告,2024年营业收入为18.34亿元,同比下降5.35%。归属于上市公司股东的净利 润为1.62亿元,同比下降26.75%。公司拟向全体股东每10股派发现金红利2.07元(含税),送红股0股(含 税),以资本公积金向全体股东每10股转增0股。 ...
理邦仪器:2025年一季度净利润6508.82万元,同比增长68.98%
news flash· 2025-04-23 11:59
理邦仪器(300206)公告,2025年第一季度营收为4.2亿元,同比下降5.25%;净利润为6508.82万元, 同比增长68.98%。 ...